Close Menu
    • ABOUT
    • BOOK STORE
    • ENTREPRENEURSHIP
    • ESG
    • EVENTS & AWARDS
    • POLITICS
    • GADGETS
    • CONTACT
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Business explainer
    Tuesday, November 17
    • TRENDING
    • EXECUTIVES
    • COMPANIES
    • STARTUPS
    • GLOBAL
    • AGRICULTURE
    • DEALS
    • Ai
    • ECONOMY
    • MOTORING
    • TECHNOLOGY
    Business explainer
    Home » Cipla Confirms Continued Support for ARV Supply
    COMPANIES

    Cipla Confirms Continued Support for ARV Supply

    February 2, 20262 Mins Read
    Share Facebook Twitter Pinterest Copy Link LinkedIn Tumblr Email Telegram WhatsApp
    Follow Us
    Google News
    Paul Miller, CEO of Cipla Africa
    Share
    Facebook Twitter LinkedIn Email Copy Link

    Cipla Medpro South Africa reaffirmed its commitment to ensuring the uninterrupted supply of critical antiretroviral (ARV) medicines to the Department of Health. It is essential that people living with HIV have uninterrupted access to these life-saving medicines. Any disruption of supply puts patients at risk of developing resistance to the drugs or adversely affecting health outcomes. According to Statistics South Africa, the number of people living with HIV in the country is estimated to be approximately 8 million (12,7% of the population)[1].

    Recently, two suppliers who were awarded the current antiretroviral (ARV) tender, Barrs Pharmaceuticals Industries (Pty) Ltd and Innovata Pharmaceuticals (Pty) Ltd (subsidiaries of Avacare Health), have entered business rescue.

    Cipla acknowledges the uncertainty this may create within the ARV supply chain and underscores its readiness to assist in maintaining stability and continuity.

    Cipla has been manufacturing tenofovir/lamivudine/dolutegravir (TLD) for the government for the past 7 years, and has been one of the main suppliers of ARVs to the government for more than 12 years. Cipla has made significant investments in its local manufacturing facility, upgrading the capacity of the ARV production line with the installation of a new Countec bottle line and have increased its tablet filing capacity by 190%. The company is able to locally produce 475 million tablets annually and has upscaled its manufacturing capabilities to ensure sufficient capacity to meet current demand and support near‑term growth, while reinforcing Cipla’s commitment to secure and reliable ARV supply.

    “We have mobilised resources to help maintain equitable access to quality, affordable critical medication. Cipla confirms its willingness to support national requirements under the current tender agreement and, if needed, contribute meaningfully to any supplementary procurement processes to safeguard patient access to essential treatment. We want people to live a long and healthy life as part of our commitment to caring for life,” said Paul Miller, CEO of Cipla Africa.

    “In addition, we believe this tender presents an opportunity to further advance government’s commitment to strengthening local manufacturing capacity. By ensuring greater support for locally produced medicines, future allocations could meaningfully contribute to South Africa’s industrial development agenda while maintaining continuity of supply,” said Miller.

    The total ARV tender is for a period of three years, and is worth an estimated R15.5bn, of which the TLD component comprises R12.6bn.

    Follow on Google News
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link WhatsApp

    Related Posts

    Cape100 Appoints Ann Ashworth as Race Director and Southpaw as Commercial Partner Ahead of 2027 Debut

    November 16, 2026

    MTN Makes Fresh Run at Telkom

    November 16, 2026

    Dipula Steps Up Buying With R3bn in Deals

    November 12, 2026

    Vodacom Profits Jump as SA Prepaid Returns to Growth

    November 11, 2026
    Top Posts

    Absa Launches Grant Fund to Back Young Entrepreneurs

    July 26, 20263,390

    Old Mutual Shareholders Reject CEO Pay Plan

    July 16, 20263,273

    PIC Board Suspends Its CEO

    July 13, 20262,940

    Avatar Confirms Ngubane’s Abrupt Exit as Co-Chief Creative Officer

    July 22, 20262,590
    Don't Miss

    What New Amazon Research Reveals About South African SMMEs

    November 17, 2026 TECHNOLOGY

    Amazon today released its Small Business Digital Adoption Report, conducted by independent research organisation World Wide Worx,…

    Africa’s Banks are Thriving. That’s Exactly the Problem

    November 16, 2026

    SA Households Owe 61% of Annual Income

    November 16, 2026

    Why Tapping Your Two-Pot Savings and December Bonus Could Cost You in January

    November 16, 2026
    Stay In Touch
    • Twitter
    • LinkedIn
    • Facebook

    Business Explainer proudly displays the “FAIR” stamp of the Press Council of South Africa, indicating our commitment to adhere to the Code of Ethics for Print and online media which prescribes that our reportage is truthful, accurate and fair. Should you wish to lodge a complaint about our news coverage, please lodge a complaint on the Press Council’s website, www.presscouncil.org.za or email the complaint to khanyim@presscouncilsa.org.za Contact the Press Council on 011 4843612.

    Facebook X (Twitter) LinkedIn
    Categories
    • TRENDING
    • EXECUTIVES
    • COMPANIES
    • STARTUPS
    • GLOBAL
    • AGRICULTURE
    • DEALS
    • Ai
    • ECONOMY
    • MOTORING
    • TECHNOLOGY
    contact us
    • Get In Touch
    Facebook X (Twitter)
    • Privacy Policy
    © 2026 Business Explainer .

    Type above and press Enter to search. Press Esc to cancel.